Data / Form D filings / AdvanCell Isotopes Pty Ltd
AdvanCell Isotopes Pty Ltd: Form D filing
AdvanCell Isotopes Pty Ltd, a biotechnology company in Sydney Nsw, Australia, filed a Form D with the SEC in 2023. The latest, on December 28, 2023, reports $5 million sold of a $10 million offering to 1 investor.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- LEVEL 7/167 MACQUAIRE ST, Sydney Nsw, Australia, 2000
- Phone
- (978) 421-6527
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Australia
- Year incorporated
- 2019
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 2006018
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Dec 28, 2023 | New notice | $10,000,000 | $5,000,000 | $5,000,000 | 1 | Dec 7, 2023 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Andrew Adamovich | Executive Officer | |
| William Ferris | Director | |
| Adrian Paterson | Director | |
| Anthony Aiudi | Director | |
| Simon Puttick | Executive Officer, Director | |
| Michael Tung | Executive Officer | |
| Kevin Cameron | Director |
Every Form D from the week of Dec 25, 2023 · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what AdvanCell Isotopes Pty Ltd reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.